Candel Therapeutics (NASDAQ:CADL) Now Covered by Analysts at Canaccord Genuity Group
Canaccord Genuity Group started coverage on shares of Candel Therapeutics (NASDAQ:CADL – Get Free Report) in a research report issued on Wednesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $20.00 price target on the stock. Canaccord Genuity Group’s price target would suggest a potential upside of 63.80% from the company’s current price. […]
Canaccord Genuity Group started coverage on shares of Candel Therapeutics (NASDAQ:CADL – Get Free Report) in a research report issued on Wednesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $20.00 price target on the stock. Canaccord Genuity Group’s price target would suggest a potential upside of 63.80% from the company’s current price. […]
